PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34359849/

Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs). However, intrinsic or acquired resistance remains a clin ...